Market Closed -
Nasdaq
04:30:00 2024-06-07 pm EDT
|
5-day change
|
1st Jan Change
|
1.02
USD
|
-2.86%
|
|
-12.07%
|
-55.46%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
43.12
|
21.38
|
24.49
|
24.43
|
-
|
-
|
Enterprise Value (EV)
1 |
43.12
|
21.38
|
24.49
|
24.43
|
24.43
|
24.43
|
P/E ratio
|
-4
x
|
-2.16
x
|
-2.31
x
|
-3.09
x
|
-2.49
x
|
-7.03
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
2
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
2
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-7,269,507
x
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-0%
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
8,908
|
9,098
|
10,694
|
23,952
|
-
|
-
|
Reference price
2 |
4.840
|
2.350
|
2.290
|
1.020
|
1.020
|
1.020
|
Announcement Date
|
3/30/22
|
3/2/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
12.19
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-
|
-5.671
|
-9.95
|
-11.4
|
-9.526
|
-12.96
|
-6.732
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-55.23%
|
Earnings before Tax (EBT)
1 |
-
|
-6.324
|
-9.889
|
-10.23
|
-7.756
|
-12.81
|
-6.582
|
Net income
1 |
-3.798
|
-6.324
|
-9.889
|
-10.23
|
-7.756
|
-12.81
|
-6.582
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-54%
|
EPS
2 |
-0.3400
|
-1.210
|
-1.090
|
-0.9900
|
-0.3300
|
-0.4100
|
-0.1450
|
Free Cash Flow
|
-
|
-5.931
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/2/21
|
3/30/22
|
3/2/23
|
4/1/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-2.356
|
-3.005
|
-2.614
|
-2.161
|
-2.17
|
-3.261
|
-3.375
|
-2.983
|
-1.777
|
-2.476
|
-2.35
|
-2.35
|
-2.35
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-2.355
|
-3.003
|
-2.594
|
-2.136
|
-2.156
|
-3.257
|
-2.327
|
-1.421
|
-3.227
|
-1.076
|
-2.21
|
-2.23
|
-2.24
|
-
|
-
|
Net income
1 |
-2.355
|
-3.003
|
-2.594
|
-2.136
|
-2.156
|
-3.257
|
-2.327
|
-1.421
|
-3.227
|
-1.076
|
-2.21
|
-2.23
|
-2.24
|
-
|
-
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.1200
|
-0.3300
|
-0.2900
|
-0.2400
|
-0.2300
|
-0.3600
|
-0.2200
|
-0.1300
|
-0.3000
|
-0.0700
|
-0.0900
|
-0.0800
|
-0.0800
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/22
|
5/13/22
|
8/12/22
|
11/14/22
|
3/2/23
|
5/12/23
|
8/16/23
|
11/13/23
|
4/1/24
|
5/10/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-5.93
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
4/2/21
|
3/30/22
|
3/2/23
|
4/1/24
|
-
|
-
|
-
|
Last Close Price
1.02
USD Average target price
3.75
USD Spread / Average Target +267.65% Consensus |
1st Jan change
|
Capi.
|
---|
| -55.46% | 24.43M | | +18.72% | 125B | | +14.19% | 108B | | -4.93% | 24.21B | | +3.23% | 22.78B | | -10.44% | 17.96B | | -41.74% | 16.43B | | -13.31% | 16.37B | | +2.44% | 13.58B | | +27.89% | 11.66B |
Bio Therapeutic Drugs
|